Co-Diagnostics, Inc.
Co-Diagnostics, Inc.
Your view on CODX
Overview
What the company does, where it operates, and who runs it.
About Co-Diagnostics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dwight H. Egan
- Headquarters
- 2401 South Foothill Drive, Salt Lake City, UT, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dwight H. Egan
- Headquarters
- 2401 South Foothill Drive, Salt Lake City, UT, US
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.
The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems.
The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Co-Diagnostics, Inc., and the rating behind it. CODX last traded at $1.12; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Co-Diagnostics, Inc.. Starting points for Co-Diagnostics, Inc.: EPS -$10.92, beta 2.85 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Co-Diagnostics, Inc.. Co-Diagnostics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Co-Diagnostics, Inc.. Trailing twelve-month EPS for Co-Diagnostics, Inc. stands at -$10.92. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Co-Diagnostics, Inc.. Co-Diagnostics, Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Co-Diagnostics, Inc. valued side by side against its closest peers. Co-Diagnostics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Co-Diagnostics, Inc., and how their positions are changing. At a $1.3M market value, institutional positions materially move Co-Diagnostics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Co-Diagnostics, Inc. executives and directors. Shares of Co-Diagnostics, Inc. have traded between $0.23 and $1.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Co-Diagnostics, Inc.. Co-Diagnostics, Inc. is a $1.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Co-Diagnostics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Co-Diagnostics, Inc.. Coverage tracks Co-Diagnostics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.